RU2704283C9 - Способы и композиции для модификации целевого локуса - Google Patents
Способы и композиции для модификации целевого локуса Download PDFInfo
- Publication number
- RU2704283C9 RU2704283C9 RU2016150168A RU2016150168A RU2704283C9 RU 2704283 C9 RU2704283 C9 RU 2704283C9 RU 2016150168 A RU2016150168 A RU 2016150168A RU 2016150168 A RU2016150168 A RU 2016150168A RU 2704283 C9 RU2704283 C9 RU 2704283C9
- Authority
- RU
- Russia
- Prior art keywords
- cell
- polynucleotide
- nuclease
- target
- nuclease agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 263
- 239000000203 mixture Substances 0.000 title abstract description 28
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 468
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 468
- 239000002157 polynucleotide Substances 0.000 claims abstract description 468
- 101710163270 Nuclease Proteins 0.000 claims abstract description 319
- 239000003550 marker Substances 0.000 claims abstract description 251
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 230
- 230000008685 targeting Effects 0.000 claims abstract description 206
- 239000013598 vector Substances 0.000 claims abstract description 142
- 230000000694 effects Effects 0.000 claims abstract description 112
- 210000004027 cell Anatomy 0.000 claims description 537
- 239000002773 nucleotide Substances 0.000 claims description 304
- 125000003729 nucleotide group Chemical group 0.000 claims description 304
- 108090000623 proteins and genes Proteins 0.000 claims description 202
- 241000282414 Homo sapiens Species 0.000 claims description 157
- 102000004169 proteins and genes Human genes 0.000 claims description 149
- 150000007523 nucleic acids Chemical class 0.000 claims description 113
- 102000039446 nucleic acids Human genes 0.000 claims description 111
- 108020004707 nucleic acids Proteins 0.000 claims description 111
- 108091033409 CRISPR Proteins 0.000 claims description 90
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 75
- 108700028369 Alleles Proteins 0.000 claims description 72
- 238000003780 insertion Methods 0.000 claims description 55
- 230000037431 insertion Effects 0.000 claims description 55
- 210000004962 mammalian cell Anatomy 0.000 claims description 52
- 238000003776 cleavage reaction Methods 0.000 claims description 49
- 230000007017 scission Effects 0.000 claims description 49
- 230000004048 modification Effects 0.000 claims description 47
- 238000012986 modification Methods 0.000 claims description 47
- 230000001105 regulatory effect Effects 0.000 claims description 42
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 41
- 241000283984 Rodentia Species 0.000 claims description 38
- 238000010354 CRISPR gene editing Methods 0.000 claims description 35
- 108091079001 CRISPR RNA Proteins 0.000 claims description 31
- 230000010354 integration Effects 0.000 claims description 30
- 108020003175 receptors Proteins 0.000 claims description 30
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 27
- 229930193140 Neomycin Natural products 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 26
- 229960004927 neomycin Drugs 0.000 claims description 26
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 24
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 18
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 17
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 17
- 230000003115 biocidal effect Effects 0.000 claims description 16
- 210000001161 mammalian embryo Anatomy 0.000 claims description 16
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 16
- 230000035897 transcription Effects 0.000 claims description 15
- 108091026890 Coding region Proteins 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 12
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 12
- 241000700584 Simplexvirus Species 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 108091008874 T cell receptors Proteins 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 10
- 108020004440 Thymidine kinase Proteins 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 229930189065 blasticidin Natural products 0.000 claims description 9
- 239000012636 effector Substances 0.000 claims description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 108700026244 Open Reading Frames Proteins 0.000 claims description 8
- 230000001537 neural effect Effects 0.000 claims description 8
- 229950010131 puromycin Drugs 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 230000008707 rearrangement Effects 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 210000000472 morula Anatomy 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 5
- 230000005782 double-strand break Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000005783 single-strand break Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 142
- 108020004414 DNA Proteins 0.000 description 129
- 241000699666 Mus <mouse, genus> Species 0.000 description 53
- 241000124008 Mammalia Species 0.000 description 40
- 241000700159 Rattus Species 0.000 description 39
- 230000000295 complement effect Effects 0.000 description 37
- 210000001236 prokaryotic cell Anatomy 0.000 description 30
- 230000027455 binding Effects 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 27
- 238000002744 homologous recombination Methods 0.000 description 23
- 230000006801 homologous recombination Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 241000699800 Cricetinae Species 0.000 description 18
- 241000282693 Cercopithecidae Species 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 108700008625 Reporter Genes Proteins 0.000 description 17
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 230000006798 recombination Effects 0.000 description 17
- 238000005215 recombination Methods 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000004568 DNA-binding Effects 0.000 description 15
- -1 promoter Substances 0.000 description 15
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 12
- 238000012239 gene modification Methods 0.000 description 12
- 230000005017 genetic modification Effects 0.000 description 12
- 235000013617 genetically modified food Nutrition 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 241000894007 species Species 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000000287 oocyte Anatomy 0.000 description 10
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 9
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 9
- 241000193996 Streptococcus pyogenes Species 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 9
- 108091092236 Chimeric RNA Proteins 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010021466 Mutant Proteins Proteins 0.000 description 7
- 102000008300 Mutant Proteins Human genes 0.000 description 7
- 108010052160 Site-specific recombinase Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 6
- 102000004533 Endonucleases Human genes 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 6
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000282994 Cervidae Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 5
- 241000282341 Mustela putorius furo Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 5
- 108010021843 fluorescent protein 583 Proteins 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 4
- 108010025815 Kanamycin Kinase Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- 241000009328 Perro Species 0.000 description 4
- 230000004570 RNA-binding Effects 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 108091005948 blue fluorescent proteins Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910052594 sapphire Inorganic materials 0.000 description 4
- 239000010980 sapphire Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 3
- 108091005944 Cerulean Proteins 0.000 description 3
- 241000579895 Chlorostilbon Species 0.000 description 3
- 108091005943 CyPet Proteins 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 102100025169 Max-binding protein MNT Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 241000545067 Venus Species 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000010976 emerald Substances 0.000 description 3
- 229910052876 emerald Inorganic materials 0.000 description 3
- 230000007159 enucleation Effects 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 210000000688 human artificial chromosome Anatomy 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- 108010045123 Blasticidin-S deaminase Proteins 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000702191 Escherichia virus P1 Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 241000187191 Streptomyces viridochromogenes Species 0.000 description 2
- 241000203587 Streptosporangium roseum Species 0.000 description 2
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 2
- 108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 210000003297 immature b lymphocyte Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 1
- 241000007910 Acaryochloris marina Species 0.000 description 1
- 241001135192 Acetohalobium arabaticum Species 0.000 description 1
- 241001464929 Acidithiobacillus caldus Species 0.000 description 1
- 241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000190857 Allochromatium vinosum Species 0.000 description 1
- 241000147155 Ammonifex degensii Species 0.000 description 1
- 241000620196 Arthrospira maxima Species 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- NTTIDCCSYIDANP-UHFFFAOYSA-N BCCP Chemical compound BCCP NTTIDCCSYIDANP-UHFFFAOYSA-N 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 1
- 101710180532 Biotin carboxyl carrier protein of acetyl-CoA carboxylase Proteins 0.000 description 1
- 241000823281 Burkholderiales bacterium Species 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241001496650 Candidatus Desulforudis Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000065716 Crocosphaera watsonii Species 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 241000159506 Cyanothece Species 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100162704 Emericella nidulans I-AniI gene Proteins 0.000 description 1
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 1
- 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 1
- 241000326311 Exiguobacterium sibiricum Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 101000744174 Homo sapiens DNA-3-methyladenine glycosylase Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100020744 Immunoglobulin iota chain Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 101710181549 Interleukin-34 Proteins 0.000 description 1
- 108091007973 Interleukin-36 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 241001430080 Ktedonobacter racemifer Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000501784 Marinobacter sp. Species 0.000 description 1
- 241000204637 Methanohalobium evestigatum Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000192710 Microcystis aeruginosa Species 0.000 description 1
- 241000190928 Microscilla marina Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 1
- 241000167285 Natranaerobius thermophilus Species 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 241000919925 Nitrosococcus halophilus Species 0.000 description 1
- 241001515112 Nitrosococcus watsonii Species 0.000 description 1
- 241000203619 Nocardiopsis dassonvillei Species 0.000 description 1
- 241001223105 Nodularia spumigena Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000192673 Nostoc sp. Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241000142651 Pelotomaculum thermopropionicum Species 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 241000983938 Petrotoga mobilis Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001599925 Polaromonas naphthalenivorans Species 0.000 description 1
- 241001472610 Polaromonas sp. Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 241000590028 Pseudoalteromonas haloplanktis Species 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020004422 Riboswitch Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241001518258 Streptomyces pristinaespiralis Species 0.000 description 1
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 1
- 241000192560 Synechococcus sp. Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 241000206213 Thermosipho africanus Species 0.000 description 1
- 241000078013 Trichormus variabilis Species 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 241001673106 [Bacillus] selenitireducens Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008832P | 2014-06-06 | 2014-06-06 | |
| US62/008,832 | 2014-06-06 | ||
| US201462017916P | 2014-06-27 | 2014-06-27 | |
| US62/017,916 | 2014-06-27 | ||
| PCT/US2015/034503 WO2015188109A1 (en) | 2014-06-06 | 2015-06-05 | Methods and compositions for modifying a targeted locus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019132992A Division RU2019132992A (ru) | 2014-06-06 | 2015-06-05 | Способы и композиции для модификации целевого локуса |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| RU2016150168A RU2016150168A (ru) | 2018-07-18 |
| RU2016150168A3 RU2016150168A3 (enExample) | 2018-12-05 |
| RU2704283C2 RU2704283C2 (ru) | 2019-10-25 |
| RU2704283C9 true RU2704283C9 (ru) | 2020-02-07 |
Family
ID=53404960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150168A RU2704283C9 (ru) | 2014-06-06 | 2015-06-05 | Способы и композиции для модификации целевого локуса |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10106820B2 (enExample) |
| EP (2) | EP3708671B1 (enExample) |
| JP (2) | JP6688231B2 (enExample) |
| KR (1) | KR102374379B1 (enExample) |
| CN (2) | CN106795521B (enExample) |
| AU (1) | AU2015269187B2 (enExample) |
| BR (1) | BR112016028564A2 (enExample) |
| CA (1) | CA2950173C (enExample) |
| CY (1) | CY1122897T1 (enExample) |
| DK (1) | DK3152312T3 (enExample) |
| ES (2) | ES2784754T3 (enExample) |
| HR (1) | HRP20200529T1 (enExample) |
| HU (1) | HUE049776T2 (enExample) |
| IL (1) | IL249042B (enExample) |
| LT (1) | LT3152312T (enExample) |
| MX (1) | MX385689B (enExample) |
| NZ (1) | NZ727481A (enExample) |
| PL (1) | PL3152312T3 (enExample) |
| PT (1) | PT3152312T (enExample) |
| RS (1) | RS60359B1 (enExample) |
| RU (1) | RU2704283C9 (enExample) |
| SG (2) | SG11201609634YA (enExample) |
| SI (1) | SI3152312T1 (enExample) |
| SM (1) | SMT202000264T1 (enExample) |
| WO (1) | WO2015188109A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| JP6275120B2 (ja) | 2012-04-25 | 2018-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 大きい標的化ベクターによるヌクレアーゼ媒介標的化 |
| JP6475172B2 (ja) | 2013-02-20 | 2019-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ラットの遺伝子組換え |
| EP3456831B1 (en) | 2013-04-16 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| ES2975317T3 (es) | 2013-12-11 | 2024-07-04 | Regeneron Pharma | Métodos y composiciones para la modificación dirigida de un genoma |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| BR112016028564A2 (pt) | 2014-06-06 | 2018-01-30 | Regeneron Pharma | método para modificar um locus-alvo em uma célula. |
| SG10201911411YA (en) | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| CA2963315A1 (en) | 2014-10-15 | 2016-04-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| CA3176380A1 (en) | 2014-11-21 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| BR112017013104A2 (pt) | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
| EP4108255A1 (en) | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| AU2016333886B2 (en) | 2015-10-05 | 2020-10-08 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| AU2017230011A1 (en) * | 2016-03-11 | 2018-09-27 | 2Seventy Bio, Inc. | Genome edited immune effector cells |
| KR20180132705A (ko) * | 2016-04-04 | 2018-12-12 | 에테하 취리히 | 단백질 생산 및 라이브러리(Library) 생성을 위한 포유동물 세포주 |
| CA3020923A1 (en) | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| WO2017201476A1 (en) * | 2016-05-20 | 2017-11-23 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
| IL263160B2 (en) | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| CN107513538A (zh) * | 2016-06-17 | 2017-12-26 | 北京大学 | 基因敲除方法 |
| US20180004537A1 (en) | 2016-07-01 | 2018-01-04 | Microsoft Technology Licensing, Llc | Molecular State Machines |
| US11359234B2 (en) * | 2016-07-01 | 2022-06-14 | Microsoft Technology Licensing, Llc | Barcoding sequences for identification of gene expression |
| US10669558B2 (en) | 2016-07-01 | 2020-06-02 | Microsoft Technology Licensing, Llc | Storage through iterative DNA editing |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| MA53935A (fr) | 2016-11-04 | 2021-12-22 | Regeneron Pharma | Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| SG10202109874VA (en) | 2017-01-19 | 2021-10-28 | Open Monoclonal Tech Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| WO2018151514A1 (ko) * | 2017-02-16 | 2018-08-23 | 고려대학교 산학협력단 | 골재생 효능이 우수한 골질환 예방 또는 치료용 조성물 |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3056182A1 (en) * | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| AU2018292526A1 (en) | 2017-06-30 | 2020-01-16 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| CN111094573A (zh) * | 2017-07-12 | 2020-05-01 | 梅约医学教育与研究基金会 | 有效靶向敲入或基因置换的材料和方法 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| MX2020001998A (es) * | 2017-08-21 | 2020-10-05 | Univ Tokushima | Tecnología de alteración específica de secuencia objetivo utilizando reconocimiento de objetivos del nucleotído. |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CN111315889A (zh) * | 2017-09-08 | 2020-06-19 | 生命技术公司 | 提高同源重组的方法和其组合物 |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| US20210017544A1 (en) * | 2017-12-22 | 2021-01-21 | Novozymes A/S | Counter-Selection by Inhibition of Conditionally Essential Genes |
| CN107904208B (zh) * | 2017-12-25 | 2019-11-01 | 云舟生物科技（广州）有限公司 | 细胞表型研究用的细胞克隆及其筛选方法和应用 |
| JP7075170B2 (ja) * | 2018-01-23 | 2022-05-25 | インスティチュート フォー ベーシック サイエンス | 延長された単一ガイドｒｎａ及びその用途 |
| BR112020015798A2 (pt) | 2018-02-01 | 2021-03-09 | Homology Medicines, Inc. | Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| WO2019200122A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| KR20210018273A (ko) * | 2018-05-04 | 2021-02-17 | 로커스 바이오사이언스, 인크. | 표적 박테리아를 사멸시키기 위한 방법 및 조성물 |
| KR20210045360A (ko) | 2018-05-16 | 2021-04-26 | 신테고 코포레이션 | 가이드 rna 설계 및 사용을 위한 방법 및 시스템 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| JP7233545B2 (ja) * | 2018-12-30 | 2023-03-06 | エフ． ホフマン－ラ ロシュ アーゲー | 標的タンパク質への検出可能なタグのＣＲＩＳＰＲ／Ｃａｓ制御組み込みに基づく細胞の選択方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| ES2923629T3 (es) * | 2019-04-04 | 2022-09-29 | Regeneron Pharma | Métodos para la introducción sin cicatrices de modificaciones dirigidas en vectores de direccionamiento |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020232081A2 (en) * | 2019-05-13 | 2020-11-19 | Rapid Genomics Llc | Capture and analysis of target genomic regions |
| EP4004216A1 (en) * | 2019-07-25 | 2022-06-01 | Precision BioSciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021119594A1 (en) * | 2019-12-13 | 2021-06-17 | The Regents Of The University Of California | Reducing antibiotic resistance in bacteria using pro-active genetics |
| IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| US20240018493A1 (en) * | 2020-11-10 | 2024-01-18 | The Board Of Trustees Of The Leland Stanford Junior University | Knock-in of large dna for long-term high genomic expression |
| CN114763559B (zh) * | 2021-01-15 | 2024-07-19 | 中国农业大学 | 一种不依赖于同源重组的靶向性基因捕获系统及其应用 |
| JP2024533683A (ja) * | 2021-09-24 | 2024-09-12 | イムノカン バイオテック カンパニー リミテッド | 大型染色体の導入方法と改変染色体およびそれを用いた生物 |
| CN121079425A (zh) * | 2023-05-10 | 2025-12-05 | 武田药品工业株式会社 | 可再编辑的模板、细胞、组合物和制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063361A1 (en) * | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
| WO2013163394A1 (en) * | 2012-04-25 | 2013-10-31 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
| WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| WO1999005266A2 (en) | 1997-07-26 | 1999-02-04 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| DE69841578D1 (de) * | 1997-09-16 | 2010-05-06 | Centocor Inc | Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen |
| EP1141360A4 (en) | 1998-12-31 | 2002-11-06 | David Gladstone Inst | Transgenic rodents and rodent cell lines that express HIV receptors. |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| AU776576B2 (en) | 1999-12-06 | 2004-09-16 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US7026462B2 (en) | 2000-12-07 | 2006-04-11 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7947469B2 (en) | 2001-01-22 | 2011-05-24 | Gendaq, Ltd. | Modulation of HIV infection |
| CA2435394C (en) | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
| AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
| US20030082591A1 (en) | 2001-07-24 | 2003-05-01 | Donald Awrey | Methods for gene disruption and uses thereof |
| WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| WO2003078619A1 (en) | 2002-03-15 | 2003-09-25 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| JP2006502748A (ja) | 2002-09-05 | 2006-01-26 | カリフォルニア インスティテュート オブ テクノロジー | 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法 |
| WO2004031346A2 (en) | 2002-09-06 | 2004-04-15 | Fred Hutchinson Cancer Research Center | Methods and compositions concerning designed highly-specific nucleic acid binding proteins |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| JP2006517101A (ja) | 2003-01-13 | 2006-07-20 | エス． ラオ、マヘンドラ | 治療用産物を送達するための、増殖性の幹細胞および前駆細胞における候補分子の持続的発現 |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1591521A1 (en) | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
| AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| WO2006097854A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | Heterodimeric meganucleases and use thereof |
| US20070004041A1 (en) | 2005-06-30 | 2007-01-04 | Codon Devices, Inc. | Heirarchical assembly methods for genome engineering |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| EP2505058A1 (en) | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
| EP2092068B1 (en) | 2006-12-14 | 2014-10-08 | Dow AgroSciences LLC | Optimized non-canonical zinc finger proteins |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
| EP2602323B1 (en) | 2007-06-01 | 2018-02-28 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
| WO2009076464A2 (en) | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
| CN102625655B (zh) | 2008-12-04 | 2016-07-06 | 桑格摩生物科学股份有限公司 | 使用锌指核酸酶在大鼠中进行基因组编辑 |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| CA2755192C (en) | 2009-03-20 | 2018-09-11 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
| WO2010127111A1 (en) | 2009-04-30 | 2010-11-04 | The Trustees Of Comlumbia University In The City Of New York | In vivo assembly of dna via homologous recombination |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| EP3028565B1 (en) * | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| US20120178647A1 (en) | 2009-08-03 | 2012-07-12 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
| EP2493288B1 (en) | 2009-10-28 | 2015-02-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
| TR201903376T4 (tr) | 2009-10-29 | 2019-04-22 | Regeneron Pharma | Çok fonksiyonlu alleller. |
| WO2011053957A2 (en) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions and methods for the regulation of multiple genes of interest in a cell |
| CN102762717A (zh) | 2009-12-01 | 2012-10-31 | 日本国立癌症研究中心 | 使用大鼠胚胎干细胞构建嵌合大鼠的方法 |
| CA2783351C (en) | 2009-12-10 | 2021-09-07 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| EP2516652B1 (en) | 2009-12-21 | 2014-11-05 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| JP2013517774A (ja) | 2010-01-22 | 2013-05-20 | ダウ アグロサイエンシィズ エルエルシー | 遺伝子改変生物における導入遺伝子の切除 |
| WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| WO2011156723A1 (en) | 2010-06-11 | 2011-12-15 | Regeneron Pharmaceuticals, Inc. | Production of fertile xy female animals from xy es cells |
| NZ605966A (en) * | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| WO2012018726A1 (en) | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| BR112014027813A2 (pt) | 2012-05-07 | 2017-08-08 | Dow Agrosciences Llc | métodos e composições para integração de transgenes direcionada mediada por nuclease |
| KR101656236B1 (ko) | 2012-10-23 | 2016-09-12 | 주식회사 툴젠 | 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도 |
| PT3363902T (pt) | 2012-12-06 | 2019-12-19 | Sigma Aldrich Co Llc | Modificação e regulação de genoma baseadas em crispr |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR20150105956A (ko) | 2012-12-12 | 2015-09-18 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| ES2576126T3 (es) | 2012-12-12 | 2016-07-05 | The Broad Institute, Inc. | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| EP4282970A3 (en) | 2012-12-17 | 2024-01-17 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| JP6583918B2 (ja) | 2012-12-27 | 2019-10-02 | キージーン ナムローゼ フェンノートシャップ | 植物における遺伝連鎖を解消するための方法 |
| JP6475172B2 (ja) | 2013-02-20 | 2019-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ラットの遺伝子組換え |
| JP2016507244A (ja) | 2013-02-27 | 2016-03-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集 |
| US10612043B2 (en) | 2013-03-09 | 2020-04-07 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events |
| US9234213B2 (en) * | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| EP2975942B1 (en) * | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| EP2981617B1 (en) | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
| EP3456831B1 (en) | 2013-04-16 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| AU2014265331B2 (en) | 2013-05-15 | 2019-12-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
| EP3004349B1 (en) | 2013-05-29 | 2018-03-28 | Cellectis S.A. | A method for producing precise dna cleavage using cas9 nickase activity |
| US20160145645A1 (en) | 2013-06-19 | 2016-05-26 | Sigma-Aldrich Co. Llc | Targeted integration |
| EP3988649B1 (en) | 2013-09-18 | 2024-11-27 | Kymab Limited | Methods, cells and organisms |
| WO2015052231A2 (en) | 2013-10-08 | 2015-04-16 | Technical University Of Denmark | Multiplex editing system |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| EP3080275B1 (en) | 2013-12-13 | 2020-01-15 | Cellectis | Method of selection of transformed diatoms using nuclease |
| US10233456B2 (en) | 2014-01-30 | 2019-03-19 | The Board Of Trustees Of The University Of Arkansas | Method, vectors, cells, seeds and kits for stacking genes into a single genomic site |
| US20170076039A1 (en) | 2014-04-24 | 2017-03-16 | Institute For Basic Science | A Method of Selecting a Nuclease Target Sequence for Gene Knockout Based on Microhomology |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| BR112016028564A2 (pt) | 2014-06-06 | 2018-01-30 | Regeneron Pharma | método para modificar um locus-alvo em uma célula. |
| SG10201911411YA (en) | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| CA2963315A1 (en) | 2014-10-15 | 2016-04-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| CA3176380A1 (en) | 2014-11-21 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| BR112017013104A2 (pt) | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
| GB201504223D0 (en) | 2015-03-12 | 2015-04-29 | Genome Res Ltd | Biallelic genetic modification |
| US20200392538A1 (en) | 2017-08-30 | 2020-12-17 | President And Fellows Of Harvard College | Iterative genome assembly |
-
2015
- 2015-06-05 BR BR112016028564A patent/BR112016028564A2/pt not_active Application Discontinuation
- 2015-06-05 HU HUE15729724A patent/HUE049776T2/hu unknown
- 2015-06-05 JP JP2016571271A patent/JP6688231B2/ja active Active
- 2015-06-05 HR HRP20200529TT patent/HRP20200529T1/hr unknown
- 2015-06-05 CA CA2950173A patent/CA2950173C/en active Active
- 2015-06-05 SM SM20200264T patent/SMT202000264T1/it unknown
- 2015-06-05 US US14/731,914 patent/US10106820B2/en active Active
- 2015-06-05 CN CN201580042190.6A patent/CN106795521B/zh active Active
- 2015-06-05 NZ NZ727481A patent/NZ727481A/en not_active IP Right Cessation
- 2015-06-05 PL PL15729724T patent/PL3152312T3/pl unknown
- 2015-06-05 CN CN202110522776.XA patent/CN113215196B/zh active Active
- 2015-06-05 EP EP20155939.0A patent/EP3708671B1/en active Active
- 2015-06-05 SG SG11201609634YA patent/SG11201609634YA/en unknown
- 2015-06-05 LT LTEP15729724.3T patent/LT3152312T/lt unknown
- 2015-06-05 SG SG10201913804WA patent/SG10201913804WA/en unknown
- 2015-06-05 DK DK15729724.3T patent/DK3152312T3/da active
- 2015-06-05 AU AU2015269187A patent/AU2015269187B2/en active Active
- 2015-06-05 SI SI201531148T patent/SI3152312T1/sl unknown
- 2015-06-05 ES ES15729724T patent/ES2784754T3/es active Active
- 2015-06-05 WO PCT/US2015/034503 patent/WO2015188109A1/en not_active Ceased
- 2015-06-05 KR KR1020167037057A patent/KR102374379B1/ko active Active
- 2015-06-05 ES ES20155939T patent/ES3019688T3/es active Active
- 2015-06-05 PT PT157297243T patent/PT3152312T/pt unknown
- 2015-06-05 RU RU2016150168A patent/RU2704283C9/ru active
- 2015-06-05 EP EP15729724.3A patent/EP3152312B1/en active Active
- 2015-06-05 MX MX2016016133A patent/MX385689B/es unknown
- 2015-06-05 RS RS20200430A patent/RS60359B1/sr unknown
-
2016
- 2016-11-17 IL IL249042A patent/IL249042B/en unknown
-
2017
- 2017-04-07 US US15/482,255 patent/US10294494B2/en active Active
-
2019
- 2019-03-29 US US16/369,565 patent/US12060571B2/en active Active
-
2020
- 2020-04-03 JP JP2020067276A patent/JP7154248B2/ja active Active
- 2020-04-13 CY CY20201100345T patent/CY1122897T1/el unknown
-
2024
- 2024-07-03 US US18/763,490 patent/US20240352489A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063361A1 (en) * | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
| WO2013163394A1 (en) * | 2012-04-25 | 2013-10-31 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
| WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
Non-Patent Citations (4)
| Title |
|---|
| ALEXANDRA E. BLOOR et al. An Efficient Method of Selectable Marker Gene Excision by Xer Recombination for Gene Replacement in Bacterial Chromosomes. Appl Environ Microbiol. 2006 Apr; 72(4): 2520-2525. * |
| ALEXANDRA E. BLOOR et al. An Efficient Method of Selectable Marker Gene Excision by Xer Recombination for Gene Replacement in Bacterial Chromosomes. Appl Environ Microbiol. 2006 Apr; 72(4): 2520-2525. DAVID W. MELTON et al. Stability of HPRT Marker Gene Expression at Different Gene-Targeted Loci: Observing and Overcoming a Position Effect. Nucleic Acids Research, Volume 25, Issue 19, 1 October 1997, Pages 3937-3943. * |
| DAVID W. MELTON et al. Stability of HPRT Marker Gene Expression at Different Gene-Targeted Loci: Observing and Overcoming a Position Effect. Nucleic Acids Research, Volume 25, Issue 19, 1 October 1997, Pages 3937-3943. * |
| Б.ГЛИК. Молекулярная биотехнология. Мир. Москва. 2002 г., стр. 483-510. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240352489A1 (en) | Methods and compositions for modifying a targeted locus | |
| JP7095066B2 (ja) | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 | |
| DK3161128T3 (en) | METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF | |
| HK40035693A (en) | Methods and compositions for modifying a targeted locus | |
| HK1235817A1 (en) | Methods and compositions for modifying a targeted locus | |
| HK1235817B (en) | Methods and compositions for modifying a targeted locus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification |